Techno Trends
TechnoTrends provide comprehensive coverage of the innovations and inventions in pharma products and pharma technologies across the world. The up-to-date listing of latest pharmaceutical product news and technology trends in the global pharma industry, keeps you abreast with all the latest pharmaceutical innovations happening world over.
New Simoa® phospho-Tau 181 (pTau-181) Blood Test Discovered for Alzheimer’s Disease
Quanterix Corporation discovers new Blood-Based pTau-181 Assay for Alzheimer’s Disease. The Simoa® phospho-Tau 181 (pTau-181) blood test will be used for diagnostic evaluation of Alzheimer’s Disease (AD). With the use of HD-X immunoassay system, the pTau-181 concentration in human serum...
Genentech Developed Breakthrough Therapy Gantenerumab for Alzheimer’s Disease
Genentech developed a breakthrough therapy for the treatment of patients living with early Alzheimer's disease (AD). This will be the first medicine to treat Alzheimer’s disease at-home administration. Gantenerumab is the first investigational IgG1 antibody designed with late-stage trials for the treatment of AD...
Novel Novilase® Interstitial Laser System Developed for Breast Cancer
Novian Health Inc. developed Novilase® Interstitial Laser System for the treatment of malignant breast tumors for adult women who undergo breast conserving procedure. The laser therapy helps patients by keeping away from trauma and works as an alternative for breast cancer surgery....
Jardiance® Novel Therapy Developed for the Treatment of Patients with Heart Failure
Eli Lilly and Company in combination with Boehringer Ingelheim has developed Jardiance®, a novel therapy to treat patients with heart failure with preserved ejection fraction (HFpEF). Jardiance is used to lower the blood sugar levels along with diet and exercise in adults with type 2 diabetes, lessens the risk of cardiovascular...
Amdizalisib (HMPL-689) Discovered for the Treatment of Relapsed or Refractory Follicular Lymphoma
Hutchmed Limited discovered novel therapy amdizalisib (HMPL-689), for the treatment of relapsed or refractory follicular lymphoma (“FL”). Amdizalisib is an inhibitor for PI3Kδ (phosphoinositide 3-kinase delta),a lipid kinase which helps in controlling the activation of several important signaling proteins...
Novel Phoenix® Therapy Developed to Treat PTSD
Evren Technologies developed Phoenix®, a novel therapy for the treatment of Post-traumatic Stress Disorder (PTSD). The Phoenix® is an earbud device which delivers a light electrical tingle to activate vagus nerve consisting of a calming effect on the body and also helps in reducing the symptoms of PTSD....
Genentech Developed Breakthrough Therapy Venclexta for Myelodysplastic Syndromes
Genentech developed Venclexta in combination with Azacitidine for the treatment of patients with Myelodysplastic Syndromes. Venclexta in combination with Azacitidine has the ability to treat adult patients who have formerly untreated with intermediate, high- and very high-risk myelodysplastic...
Novel Therapy, Toripalimab, Discovered for the Treatment of Nasopharyngeal Carcinoma
Nasopharyngeal Carcinoma in combination with Coherus discovered Toripalimab, novel therapy for the treatment of recurrent or metastatic nasopharyngeal carcinoma. Toripalimab, is an anti-PD-1 monoclonal antibodyhaving the ability to block PD-1interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function)....
Adagrasib Discovered for the Treatment of Advanced Non-Small Cell Lung Cancer
Mirati Therapeutics discovered novel therapy, Adagrasib for the treatment of patients with non-small cell lung cancer (NSCLC) harbouring the KRASG12C Mutation. Adagrasib is an investigational, selective and oral small-molecule inhibitor of KRASG12C which is developed to support target inhibition, as KRASG12C protein regenerates...
A Novel Oral Therapy TTP399 Discovered to Treat Type 1 DiabetesPatients
vTv Therapeutics discovered TTP399 therapy for the treatment of patients with Type 1 diabetes. TTP399 is a novel, oral, investigational once-daily glucokinase activator. It is considered to be an adjunctive therapy to insulin for the treatment...
